Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10547284 | 0.87 | KMT2A (0.46) | LMNAKMT2AMAPTSMN1; SMN2TDP1 | |
| SCHEMBL2554055 | 0.83 | AKR1B1 (0.55) | LMNAKMT2AMAPTTDP1KDM4E | |
| Hydrochloric Acid SCHEMBL10582878 | 0.81 | AKR1B1 (0.53) | LMNAKMT2AMAPTTDP1KDM4E | |
| SCHEMBL7196858 | 0.80 | MAPT (0.61) | LMNAKMT2AMAPTSMN1; SMN2TDP1 | |
| SCHEMBL13518029 | 0.80 | SIGMAR1 (0.49) | LMNAKMT2AMAPTSMN1; SMN2TDP1 | |
| SCHEMBL9272837 | 0.79 | LPAR1 (0.46) | LMNAKMT2ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL10864953 | 0.79 | L3MBTL1 (0.46) | LMNAKMT2ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL6546538 | 0.79 | LMNA (0.40) | LMNAKMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL10836426 | 0.79 | GABRA1 (0.46) | LMNAKMT2AMAPTSMN1; SMN2TDP1 | |
| SCHEMBL29718608 | 0.78 | HSP90AA1 (0.47) | LMNAKMT2ASMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517828-B2 | Chiral broensted acid catalyst for asymmetric synthesis and method of asymmetric synthesis with the catalyst | TOAGOSEI CO., LTD. (JP) | 2009-04-14 | — | — | US | disclosed |
| CN-100410234-C | Catalyst for asymmetric synthesis using chiral Bronsted acid and asymmetric synthesis method using the same | TOAGOSEI CO LTD (JP) | 2008-08-13 | — | — | CN | disclosed |
| US-20060276329-A1 | Asymmetric synthesis catalyst based on chiral brsnsted acid and method of asymmetric synthesis with the catalyst | TOAGOSEI CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| CN-1780810-A | Asymmetric-synthesis catalyst based on chiral broensted acid and method of asymmetric synthesis with the catalyst | TOAGOSEI CO LTD (JP) | 2006-05-31 | — | — | CN | disclosed |
| EP-1623971-A1 | ASYMMETRIC-SYNTHESIS CATALYST BASED ON CHIRAL BROENSTED ACID AND METHOD OF ASYMMETRIC SYNTHESIS WITH THE CATALYST | TOAGOSEI CO., LTD. (JP) | 2006-02-08 | — | — | EP | disclosed |
| EP-1038877-B1 | Binaphthol monophosphoric acid derivative and its use | TOSOH CORP (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-6274745-B1 | CATALYST | TOSOH CORPORATION (JP) | 2001-08-14 | — | — | US | disclosed |
| EP-1038877-A1 | Binaphthol monophosphoric acid derivative and its use | Tosoh Corporation (JP) | 2000-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276329-A1 | Asymmetric synthesis catalyst based on chiral brsnsted acid and method of asymmetric synthesis with the catalyst | LSS, COASY, FASN | LMNA 1162/4885KMT2A 2039/4885MAPT 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.